ALX Oncology’s $208 Million Public Offering


Wilson Sonsini Goodrich & Rosati advised ALX Oncology Holdings Inc. on the deal.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, announced the closing of its previously announced underwritten public offering of 2,737,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 357,000 additional shares of its common stock, at a price to the public of $76 per share. The aggregate gross proceeds to ALX Oncology from the offering were approximately $208 million. All of the shares were offered by ALX Oncology.

Jefferies, Credit Suisse, and Piper Sandler acted as joint book-running managers for the offering. Cantor and UBS Investment Bank also acted as book-running managers for the offering. In addition, LifeSci Capital acted as lead manager for the offering.

The Wilson Sonsini team advising ALX Oncology includes the following attorneys: Ken Clark (Picture), Tony Jeffries, Michael Coke, Christina Poulsen, Tae Sang Yoo, Joe Milner, Kexi Wang and Mary O’Brien.

Involved fees earner: Kenneth Clark – Wilson Sonsini Goodrich & Rosati; Michael Coke – Wilson Sonsini Goodrich & Rosati; Tony Jeffries – Wilson Sonsini Goodrich & Rosati; Joe Milner – Wilson Sonsini Goodrich & Rosati; Mary O’Brien – Wilson Sonsini Goodrich & Rosati; Christina Poulsen – Wilson Sonsini Goodrich & Rosati; Tae Sang Yoo – Wilson Sonsini Goodrich & Rosati; Kexi Wang – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: ALX Oncology Holdings Inc.;

Avatar

Author: Ambrogio Visconti